Bloating: What Could Be Causing It and When to See a Doctor

How Common Is Bloating, Really?

Bloating is one of the most frequently reported gastrointestinal symptoms worldwide. A 2022 meta-analysis published in Clinical Gastroenterology and Hepatology pooled data from 58 studies across 34 countries, finding that functional bloating or abdominal distension affected approximately 16.5% of the global population when measured by Rome IV criteria 1. Older Rome III definitions captured even higher rates, approaching 31%.

The symptom shows a clear sex-based skew. Women report bloating roughly 1.5 to 2 times more often than men, a gap that persists across cultures and age brackets 2. Hormonal fluctuation during the luteal phase of the menstrual cycle contributes, with progesterone slowing colonic transit and amplifying gas retention. Bloating also increases with age, peaks in the fourth and fifth decades, and correlates with higher body mass index, anxiety, and a history of abdominal surgery.

The economic burden is not trivial. A U.S. survey estimated that adults with frequent bloating made 1.5 to 2 more outpatient visits per year than age-matched controls, and roughly 10% of those visits led to imaging or endoscopy 3. Understanding the differential diagnosis prevents unnecessary workup while catching the small percentage of cases that signal something dangerous.

Functional Gastrointestinal Disorders: The Leading Cause

The single most common explanation for recurrent bloating is a functional gastrointestinal disorder, with IBS at the top of the list. In a Rome Foundation survey of over 73,000 adults, bloating was reported by 76% of those meeting IBS criteria and by 96% of those with IBS-constipation (IBS-C) 4.

Functional bloating (Rome IV) occupies its own diagnostic category, separate from IBS. The distinction matters: patients with functional bloating lack the pain-predominant pattern of IBS but still experience recurrent feelings of abdominal fullness or visible distension at least one day per week for three months 5. Visceral hypersensitivity plays a role in both conditions. Balloon distension studies show that IBS patients perceive discomfort at lower rectal volumes than controls, meaning a normal amount of intestinal gas feels abnormal.

Functional dyspepsia also drives upper-abdominal bloating. The Leuven Dyspepsia cohort found that postprandial fullness and early satiety were the dominant symptoms in 61% of functional dyspepsia patients, with bloating ranking as the most bothersome co-symptom in nearly half 6. Prokinetics such as itopride (not available in the U.S.) and low-dose tricyclics have shown modest benefit in randomized trials. Buspirone 10 mg before meals improved gastric accommodation in a Mayo Clinic crossover trial 7.

SIBO and the Breath Test Question

Small intestinal bacterial overgrowth (SIBO) remains one of the most debated contributors to bloating. The concept is straightforward: bacteria that normally reside in the colon migrate upstream into the small intestine, fermenting carbohydrates before they can be absorbed. The result is hydrogen and methane gas production, distension, and often diarrhea.

Prevalence estimates vary wildly depending on the diagnostic method. Glucose hydrogen breath testing identifies SIBO in roughly 30% to 40% of patients with IBS-like bloating, while jejunal aspirate culture (the traditional reference standard, defined as >10^3 colony-forming units per mL under the 2020 AGA guideline update) detects overgrowth in a partially overlapping but distinct subset 8.

Rifaximin 550 mg three times daily for 14 days remains the best-studied antibiotic for non-constipated SIBO. The TARGET 1 and TARGET 2 trials (combined N=1,260) showed that rifaximin significantly improved global IBS symptoms, including bloating, compared to placebo (40.8% vs. 31.2%, P=0.01), with effects lasting up to 10 weeks after a single course 9. For methane-predominant overgrowth (now termed intestinal methanogen overgrowth, or IMO), a combination of rifaximin plus neomycin or rifaximin plus metronidazole shows higher eradication rates than rifaximin alone.

Dr. Mark Pimentel of Cedars-Sinai has noted: "Methane is not just a marker of microbial activity. It directly slows intestinal transit. Patients with high methane on breath testing are far more likely to present with constipation-predominant symptoms and distension."

Dietary Triggers: FODMAPs, Fiber, and Fructose

Diet is the most modifiable factor in bloating. The low-FODMAP approach, developed at Monash University, restricts fermentable oligosaccharides, disaccharides, monosaccharides, and polyols for a 2-to-6-week elimination phase followed by structured reintroduction.

The evidence base is substantial. A 2021 systematic review in The Lancet Gastroenterology & Hepatology pooled nine RCTs (N=596 IBS patients) and found that a low-FODMAP diet reduced bloating severity by a standardized mean difference of 0.42 compared to control diets 10. Roughly 50% to 80% of IBS patients experience meaningful bloating relief during the elimination phase.

Specific triggers deserve attention. Lactose malabsorption affects an estimated 68% of the global population, with prevalence exceeding 90% in East Asian populations 11. Fructose malabsorption (positive on a 25-gram fructose breath test) appears in 30% to 40% of Western populations. Excess fiber can paradoxically worsen bloating, particularly insoluble fiber supplements like wheat bran. The British Dietetic Association guidelines recommend soluble fiber (psyllium) over insoluble fiber for IBS-related bloating 12.

Sugar alcohols (sorbitol, mannitol, xylitol) found in sugar-free gums, candies, and many "keto" products are among the most potent gas-producing compounds per gram ingested. A single 10-gram dose of sorbitol can provoke bloating in over 50% of healthy adults.

Motility Disorders and Gastroparesis

When food moves too slowly through the GI tract, fermentation time increases and gas accumulates. This makes dysmotility a major contributor to bloating, especially in patients who also report nausea, early satiety, and post-meal fullness.

Gastroparesis (defined by a 4-hour gastric retention of >10% on scintigraphy) affects an estimated 2% of the U.S. population. Diabetes is the most recognized cause, but idiopathic gastroparesis accounts for roughly 36% of cases in tertiary referral cohorts 13. The NIDDK Gastroparesis Clinical Research Consortium found that bloating was the second most bothersome symptom (after nausea) in 243 patients followed prospectively.

Chronic intestinal pseudo-obstruction and colonic inertia represent the severe end of the motility spectrum. These conditions produce profound distension without mechanical obstruction and often require specialized testing, including wireless motility capsule studies or antroduodenal manometry.

Pharmacologic slowing of transit is equally important. Opioids cause bloating through mu-receptor-mediated inhibition of peristalsis. GLP-1 receptor agonists (semaglutide, tirzepatide) also delay gastric emptying. The STEP-1 trial (N=1,961) reported nausea, constipation, and abdominal distension in 44%, 24%, and 7% of semaglutide 2.4 mg recipients, respectively 14. Patients starting these medications should be counseled that bloating may be dose-dependent and often improves with slower titration.

Hormonal and Gynecologic Causes

Premenstrual bloating is not imagined. Progesterone slows colonic transit by 10% to 20% during the luteal phase, and water retention amplifies the sensation of distension. A prospective diary study of 156 women found that 75% reported bloating during the five days preceding menstruation, with severity correlating to serum progesterone levels 15.

Endometriosis involving the bowel, present in 5% to 12% of women with the condition, can produce cyclical bloating that mimics IBS. A 2019 analysis in Fertility and Sterility found that women with biopsy-confirmed endometriosis were 2.5 times more likely to carry a prior IBS diagnosis than controls 16.

Polycystic ovary syndrome (PCOS) intersects with bloating through insulin resistance and altered gut motility. Hypothyroidism, which affects roughly 5% of the U.S. adult population, slows gut transit and should be excluded with a TSH level in any patient with new-onset constipation-predominant bloating 17.

Celiac Disease, Wheat Sensitivity, and Carbohydrate Malabsorption

Celiac disease affects approximately 1% of the global population, yet the average time from symptom onset to diagnosis remains 6 to 10 years in multiple cohort studies 18. Bloating is among the earliest and most persistent symptoms, reported by over 80% of untreated celiac patients. Screening with tissue transglutaminase IgA (tTG-IgA) is 95% to 97% sensitive when total serum IgA is normal.

Non-celiac wheat sensitivity (NCWS) is more controversial but clinically recognized. A double-blind, placebo-controlled crossover trial by Di Sabatino and colleagues (N=59) found that wheat capsules provoked significantly more bloating and abdominal pain than placebo in patients who tested negative for celiac disease and wheat allergy 19. Whether the trigger is gluten, fructans (a FODMAP in wheat), or amylase-trypsin inhibitors remains unresolved.

Sucrase-isomaltase deficiency, once thought rare, may cause bloating in up to 2% to 9% of patients diagnosed with IBS-D, based on genetic variant analysis 20.

Red Flags: When Bloating Signals Something Serious

Most bloating is benign. But a small subset of patients harbor conditions that demand rapid evaluation.

The NICE ovarian cancer guideline (updated 2024) identifies persistent bloating occurring on most days for fewer than 12 months as a recognized symptom warranting serum CA-125 and transvaginal ultrasound in women over 50 21. Ovarian cancer is the fifth leading cause of cancer death among women in the U.S., with approximately 19,680 new cases and 12,740 deaths estimated in 2024 by the American Cancer Society.

Dr. Rebecca Stone, a gynecologic oncologist at Johns Hopkins, has stated: "The average woman with ovarian cancer sees three to four physicians before diagnosis. Bloating is often dismissed as dietary or stress-related. We need primary care providers to have a low threshold for CA-125 and imaging in the right clinical context."

Other red flags include:

• Unintentional weight loss exceeding 5% of body weight over 6 months
• New-onset bloating after age 50 without prior GI history
• Progressive abdominal distension with shifting dullness (suggesting ascites)
• Iron-deficiency anemia concurrent with bloating (raises concern for colorectal malignancy)
• Palpable abdominal or pelvic mass
• Family history of ovarian, colorectal, or gastric cancer

Chronic liver disease with portal hypertension can present as abdominal distension that patients describe as "bloating." A basic metabolic panel and liver function tests will screen for this. Mesenteric ischemia, pancreatic insufficiency (fecal elastase <200 mcg/g), and superior mesenteric artery syndrome are rarer but should be considered in the right clinical picture.

Evidence-Based Treatment Options

Treatment depends entirely on the underlying cause, but several approaches have broad applicability across functional bloating.

Low-FODMAP diet remains first-line for IBS-related bloating. The Monash University protocol involves 2 to 6 weeks of elimination followed by systematic reintroduction. Working with a registered dietitian trained in FODMAP application improves adherence and prevents unnecessary long-term restriction 10.

Rifaximin (Xifaxan) 550 mg TID for 14 days is FDA-approved for IBS-D. The TARGET trials demonstrated a number needed to treat (NNT) of 10.5 for global IBS symptom relief 9.

Peppermint oil in enteric-coated capsules (180 to 200 mg, two to three times daily before meals) reduces smooth muscle spasm. A 2019 meta-analysis of 12 RCTs (N=835) found peppermint oil superior to placebo for global IBS symptoms, including bloating, with an NNT of 3 22.

Linaclotide (Linzess) 290 mcg daily for IBS-C targets the guanylate cyclase-C receptor, increasing fluid secretion and accelerating transit. In the Phase III trial (N=800), 33.7% of linaclotide patients achieved the primary composite endpoint versus 13.9% on placebo (P<0.001), with bloating severity improving significantly by week 4 23.

Probiotics show strain-specific effects. Bifidobacterium infantis 35624 (Alflorex) reduced bloating in a 4-week RCT of 362 women with IBS, though effect sizes were modest 24. Multi-strain products lack consistent evidence.

Simethicone (80 to 125 mg after meals) breaks gas bubbles but evidence for clinical benefit beyond placebo is weak. Activated charcoal has similarly thin support.

For patients with confirmed gastroparesis, metoclopramide 5 to 10 mg before meals (with FDA black-box awareness regarding tardive dyskinesia) remains the only FDA-approved prokinetic. Domperidone is available through the FDA's compassionate-use IND program.

Diagnostic Workup: A Stepwise Approach

A structured approach avoids both under-investigation and over-testing. For patients with bloating lasting more than 4 weeks, start with a thorough history (dietary patterns, medication list, menstrual history, family history of GI or gynecologic malignancy) and physical examination including a pelvic exam when indicated.

Tier 1 labs: CBC with differential, CMP, TSH, tTG-IgA with total IgA, CRP or ESR. These six tests cover anemia, liver/kidney disease, hypothyroidism, celiac disease, and inflammatory markers.

Tier 2 (if Tier 1 is unrevealing): hydrogen/methane breath test (lactulose or glucose substrate), fecal elastase (if steatorrhea is suspected), stool calprotectin (to differentiate functional from inflammatory pathology).

Tier 3 (targeted): abdominal/pelvic CT or ultrasound (if red flags are present), upper endoscopy with duodenal biopsies (celiac confirmation or if dyspepsia is dominant), colonoscopy (age >45 or alarm features), gastric emptying scintigraphy (suspected gastroparesis), and serum CA-125 with transvaginal ultrasound (women >50 with persistent bloating).

The American Gastroenterological Association's 2023 clinical practice update on bloating recommends against routine imaging or endoscopy in patients under 45 with no alarm features, favoring a trial of dietary therapy and symptom-based management first 25.

Patients with persistent bloating unresponsive to empiric therapy after 8 to 12 weeks should be referred to gastroenterology for further evaluation, including consideration of anorectal manometry or wireless motility capsule testing if pelvic floor dysfunction or generalized dysmotility is suspected.